Background
Methods
Results
Country | Sample Size SpA | Sample Size (Control) | Prevalence in Population | Prevalence in SpA | Prevalence in AS | OR AS/GP [95% CI] | Reference |
---|---|---|---|---|---|---|---|
Algeria | 129 AS (ESSG and NY) | 76 healthy blood donors | 4% | 69% | 54.14 [16.09–182.18] | [17] | |
Egypt | 380 normal individuals | 4.7% | [18] | ||||
Egypt | 75 SpA (ESSG) including 34 AS | 58.7% | [19] | ||||
Egypt | 100 healthy controls | 1% | [20] | ||||
Iraq | 25 AS | 2.1% | 84% | [21] | |||
Iran | 60 AS | 430 healthy blood donors | 3.95% | 66.67% | 48.59 [23.57–100.17] | [22] | |
Iran | 119 AS | 68.91% | [23] | ||||
Iran | 98 AS (NY) | 73.4% | [24] | ||||
Israel | 38 AS | 456 normal individuals | 3% | 79% | [25] | ||
Jordan | 22 AS (NY) | 75% | [26] | ||||
Jordan / Qatar | 129 AS | 2579 healthy individuals | 2.4% | 72.22% | 104.87 [66.21–166.11] | [12] | |
Kuwait | 58 SpA (27 AS) | 69.43% | 82.56% | [27] | |||
Kuwait | 35 SpA + AS patients | 544 controls | 4% | 25.7% | 8.21 [3.44–19.60] | [28] | |
Lebanon | 105 SpA (ESSG) 24 AS (NY) | 841 Rheumatolgy patients | 1.44% | 13.85% | 26.32% | 24.46 [7.78–68.19] | [29] |
Morocco | 46 AS + coxitis | 183 healthy controls | 6.16% | 58.70% | 22.09 [9.48–51.49] | [30] | |
Morocco | 49 SpA (Amor and ESSG) | 67% | [31] | ||||
Oman | 321 healthy | 0.3% | [32] | ||||
Qatar | 119 AS (NY) | 74% | [33] | ||||
Saudi Arabia | 12 AS | 66.67% | [34] | ||||
Syria | 50 AS (NY) | 217 healthy controls | 1.4% | 60% | 105.64 [29.98–381.87] | [35] | |
Tunisia | 365 AS and/or BD | 124 controls | 3.2% | 42.9% | [36] | ||
Tunisia | 100 AS (NY) | 100 healthy controls | 3% | 62% | 52.75 [15.61–178.31] | [37] | |
Tunisia | 50 AS (Amor / ESSG) | 69% | [38] | ||||
Turkey | 112 AS (NY) | 55 controls | 2.8–6.8% | 70% | 29.82 [9.99–89.05] | [39] | |
Turkey | 216 AS (67 analyzed) | 91% | [40] | ||||
UAE | 760 healthy | 6.4% | [41] | ||||
UAE | 17 AS | 56% | [42] |
Quality Indicator | Number of studies / Total studies |
---|---|
Sample size | |
- AS <30 patients | 8 / 22 |
- AS >50 patients | 12 / 22 |
Presence of control group | 11 / 27 |
Method of HLA-B27 testing stated | 3 / 27 |
Homogeneous and clear inclusion criteria | 14 / 22 |